Henri-Jean Aubin, Laurent Karila and Michel Reynaud Pages 1343 - 1350 ( 8 )
Tobacco dependence is a chronic disease that often requires repeated interventions and multiple attempts to quit. To date, three medications are FDA-approved for smoking cessation: nicotine replacement therapy, sustained-release bupropion, and varenicline. These treatments are effective across a broad range of populations, and are recommended for all smokers, including those with psychiatric or addictive comorbidity. Less is known however concerning the benefit-risk profile of these medications in pregnant women and adolescents. With these limitations in mind, clinicians should encourage and offer counseling and a prescription of pharmacotherapy to every patient willing to make a quit attempt. Despite the relative efficacy of first-line medications, many smokers relapse after one given quit attempt, and alternative pharmacotherapies are needed. Clonidine and nortriptyline have been proposed as second-line medications. In addition, this review identifies a series of promising drugs that hopefully will be available to complete our current armory.
Nicotine replacement therapy,bupropion,varenicline,psychiatric,clonidine,nortriptyline,lozenge,cessation,acetylcholine,pulsatile,alkaloids,galenic,libitum,dyspepsia,tremor,insomnia
, , Hopital Paul Brousse, 12 Avenue Paul-Vaillant-Couturier 94800 Villejuif, France.